Search

Your search keyword '"Matzinger O"' showing total 211 results
Start Over Author "Matzinger O"
211 results on '"Matzinger O"'

12. ESTRO ACROP guidelines for the delineation of lymph nodal areas in upper gastrointestinal malignancies

Author

Valentini, Vincenzo, Cellini, Francesco, Riddell, A., Brunner, T. B., Roeder, F., Giuliante, Felice, Alfieri, Sergio, Manfredi, Riccardo, Ardito, Francesco, Fiorillo, Claudio, Porziella, Venanzio, Morganti, Alessio Giuseppe, Haustermans, K., Margaritora, Stefano, De Bari, B., Matzinger, O., Gkika, E., Belka, C., Allum, W., Verheij, M., Valentini V. (ORCID:0000-0003-4637-6487), Cellini F. (ORCID:0000-0002-2145-2300), Giuliante F. (ORCID:0000-0001-9517-8220), Alfieri S. (ORCID:0000-0002-0404-724X), Manfredi R. (ORCID:0000-0002-4972-9500), Ardito F. (ORCID:0000-0003-1596-2862), Fiorillo C. (ORCID:0000-0001-7681-3567), Porziella V. (ORCID:0000-0001-6000-3172), Morganti A. G., Margaritora S. (ORCID:0000-0002-9796-760X), Valentini, Vincenzo, Cellini, Francesco, Riddell, A., Brunner, T. B., Roeder, F., Giuliante, Felice, Alfieri, Sergio, Manfredi, Riccardo, Ardito, Francesco, Fiorillo, Claudio, Porziella, Venanzio, Morganti, Alessio Giuseppe, Haustermans, K., Margaritora, Stefano, De Bari, B., Matzinger, O., Gkika, E., Belka, C., Allum, W., Verheij, M., Valentini V. (ORCID:0000-0003-4637-6487), Cellini F. (ORCID:0000-0002-2145-2300), Giuliante F. (ORCID:0000-0001-9517-8220), Alfieri S. (ORCID:0000-0002-0404-724X), Manfredi R. (ORCID:0000-0002-4972-9500), Ardito F. (ORCID:0000-0003-1596-2862), Fiorillo C. (ORCID:0000-0001-7681-3567), Porziella V. (ORCID:0000-0001-6000-3172), Morganti A. G., and Margaritora S. (ORCID:0000-0002-9796-760X)

Abstract

The European SocieTy for Radiation and Oncology -Advisory Committee on Radiation Oncology Practice (ESTRO-ACROP) endorsed a project to provide guidelines (GL) for the identification and delineation of clinically negative lymph-nodal stations (LNs) involved in upper gastrointestinal clinical scenarios. The presented GL is focused on preoperative (or definitive) setting. The project aim is to improve the consistency of clinical target volume (CTV) delineation by providing: a description of the anatomical boundaries of the LNs; a radiological computed tomography-based atlas depicting the LNs areas; a free, web-based, interactive example case for independent training of radiation oncologists on LNs delineation according to the presented GL, by both qualitative and quantitative analysis (through the FALCON EduCase platform). This project was carried out with the intention to facilitate and improve uniformity of future upper gastrointestinal guidelines on nodal CTV delineation. We report methodology and results from the collaboration of a working group panel selected by the ESTRO-ACROP.

Published
2021

15. Analyse des données regroupées de paramètres de radiothérapie externe d’essais de phase II et III de chimioradiothérapie du cancer de canal anal

Author

Rivin del Campo, E., primary, Matzinger, O., additional, Haustermans, K., additional, Bosset, J.-F., additional, Glynne-Jones, R., additional, Winter, K., additional, Konski, A., additional, Ajani, J., additional, Peiffert, D., additional, Hannoun-Lévi, J.-M., additional, Puyraveau, M., additional, Chakravarthy, B., additional, Meadows, H., additional, Northover, J., additional, Collette, L., additional, Christiaens, M., additional, and Maingon, P., additional

Published
2019
Full Text
View/download PDF

17. Nosocomial nontyphoidal salmonellosis after antineoplastic chemotherapy: reactivation of asymptomatic colonization?

Author

Delaloye, J., Merlani, G., Petignat, C., Wenger, A., Zaman, K., Monnerat, C., Matzinger, O., Beck Popovic, M., Vuichard, P., Ketterer, N., Tarr, P., Delaloye, J., Merlani, G., Petignat, C., Wenger, A., Zaman, K., Monnerat, C., Matzinger, O., Beck Popovic, M., Vuichard, P., Ketterer, N., and Tarr, P.

Abstract

An increased frequency of nontyphoidal salmonellosis is well established in cancer patients, but it is unclear whether this represents increased susceptibility to exogenous infection or opportunistic, endogenous reactivation of asymptomatic carriage. In a retrospective study, a simple case definition was used to identify the probable presence of reactivation salmonellosis in five cancer patients between 1996 and 2002. Reactivation salmonellosis was defined as the development of nosocomial diarrhea >72h after admission and following the administration of antineoplastic chemotherapy in an HIV-seronegative cancer patient who was asymptomatic on admission, in the absence of epidemiological evidence of a nosocomial outbreak. Primary salmonellosis associated with unrecognized nosocomial transmission or community acquisition and an unusually prolonged incubation period could not entirely be ruled out. During the same time period, another opportunistic infection, Pneumocystis pneumonia, was diagnosed in six cancer patients. Presumably, asymptomatic intestinal Salmonella colonization was converted to invasive infection by chemotherapy-associated intestinal mucosal damage and altered innate immune mechanisms. According to published guidelines, stool specimens from patients hospitalized for longer than 72h should be rejected unless the patient is neutropenic or ≧65 years old with significant comorbidity. However, in this study neutropenia was present in only one patient, and four patients were <65 years old. Guidelines should thus be revised in order not to reject stool culture specimens from such patients. In cancer patients, nosocomial salmonellosis can occur as a chemotherapy-triggered opportunistic reactivation infection that may be similar in frequency to Pneumocystis pneumonia

Published
2018

18. Preoperative chemotherapy and radiotherapy concomitant to cetuximab in stage IIIB NSCLC: A multicenter phase II SAKK

Author

Curioni-Fontecedro, A., primary, Ris, H.-B., additional, Xyrafas, A., additional, Bouchaab, H., additional, Gelpke, H., additional, Mach, N., additional, Matzinger, O., additional, Stojcheva, N., additional, Frueh, M., additional, Cathomas, R., additional, Berardi Vilei, S., additional, Bubendorf, L., additional, Pless, M., additional, Betticher, D., additional, and Peters, S., additional

Published
2017
Full Text
View/download PDF

19. EP-1304: Image guided intensity modulated radiotherapy for anal cancer: a multi institutional study

Author

De Bari, B., primary, Lestrade, L., additional, Franzetti Pellanda, A., additional, Jumeau, R., additional, Kountouri, M., additional, Matzinger, O., additional, Corradini, N., additional, Biggiogero, M., additional, Ballerini, G., additional, Bourhis, J., additional, Miralbell, R., additional, Ozsahin, M., additional, and Zilli, T., additional

Published
2016
Full Text
View/download PDF

20. Stereotactic body radiation therapy in stage I inoperable lung cancer: from palliative to curative options

Author

Boujelbene, N., Elloumi, F., Kamel, M.E., Abeidi, H., Matzinger, O., Mirimanoff, R.O., and Khanfir, K.

Subjects
respiratory tract diseases
Abstract

Surgery has historically been the standard of care for operable stage I non-small cell lung cancer (NSCLC). However, nearly one-quarter of patients with stage I NSCLC will not undergo surgery because of medical comorbidity or other factors. Stereotactic ablative radiotherapy (SABR) is the new standard of care for these patients. SABR offers high local tumour control rates rivalling the historical results of surgery and is generally well tolerated by patients with both peripheral and centrally located tumours. This article reviews the history of SABR for stage I NSCLC, summarises the currently available data on efficacy and toxicity, and describes some of the currently controversial aspects of this treatment.

Published
2013

27. Toxicity at three years with and without irradiation of the internal mammary and medial supraclavicular lymph node chain in stage I to III breast cancer (EORTC trial 22922/10925)

Author

Matzinger, O., Heimsoth, I., Poortmans, P., Collette, L., Struikmans, H., Bogaert, W. van den, Fourquet, A., Bartelink, H., Ataman, F., Gulyban, A., Pierart, M., Tienhoven, G. van, EORTC Radiation Oncology Grp, Breast Canc Grp, CCA -Cancer Center Amsterdam, Radiotherapy, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), and Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC )

Subjects
Oncology, MESH: Radiotherapy, MESH: Lymphatic Metastasis, MESH: Mastectomy, medicine.medical_treatment, MESH : Aged, MESH: Amino Acid Sequence, MESH : Breast Neoplasms, Severity of Illness Index, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, MESH: Protein Conformation, 0302 clinical medicine, MESH : Neoplasm Staging, MESH: Animals, Mastectomy, MESH : Protein Conformation, health care economics and organizations, MESH: Middle Aged, MESH : Amino Acid Sequence, Heart, MESH : Chemotherapy, Adjuvant, MESH : Lymphatic Metastasis, General Medicine, 3. Good health, MESH : Diabetes Mellitus, Medial supraclavicular lymph node, 030220 oncology & carcinogenesis, MESH: Diabetes Mellitus, Type 2, medicine.medical_specialty, MESH: Diabetes Mellitus, MESH: Receptor, Insulin, 03 medical and health sciences, MESH : Amyloid, Breast cancer, MESH: Severity of Illness Index, Severity of illness, Humans, MESH : Middle Aged, MESH : Islets of Langerhans, Aged, Pneumonitis, MESH: Humans, MESH: Molecular Sequence Data, MESH : Glucose, MESH : Radiotherapy, MESH: Islets of Langerhans, MESH : Humans, MESH: Adult, medicine.disease, MESH: Heart, Radiation therapy, MESH: Female, MESH: Combined Modality Therapy, MESH : Molecular Sequence Data, Pulmonary Fibrosis, 030218 nuclear medicine & medical imaging, MESH : Diabetes Mellitus, Type 2, MESH : Female, quality-assurance cardiac toxicity randomized-trial high-risk postoperative radiotherapy adjuvant radiotherapy premenopausal women radiation chemotherapy management, MESH: Aged, MESH: Neoplasm Staging, Hematology, Middle Aged, MESH : Adult, Combined Modality Therapy, humanities, MESH: Glucose, Chemotherapy, Adjuvant, MESH: Chemotherapy, Adjuvant, Lymphatic Metastasis, MESH: Monosaccharide Transport Proteins, Toxicity, Female, MESH : Severity of Illness Index, MESH : Mastectomy, Adult, Breast Neoplasms, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH : Pulmonary Fibrosis, MESH: Sequence Homology, Nucleic Acid, MESH : Heart, Internal medicine, medicine, Radiology, Nuclear Medicine and imaging, MESH : Sequence Homology, Nucleic Acid, Neoplasm Staging, MESH : Monosaccharide Transport Proteins, MESH: Amyloid, Radiotherapy, MESH: Pulmonary Fibrosis, Performance status, business.industry, MESH : Receptor, Insulin, MESH : Animals, MESH : Combined Modality Therapy, business, MESH: Breast Neoplasms
Abstract

National audience; INTRODUCTION: The EORTC 22922/10925 trial investigated the potential survival benefit and toxicity of elective irradiation of the internal mammary and medial supraclavicular (IM-MS) nodes Accrual completed in January 2004 and first results are expected in 2012. We present the toxicity reported until year 3 after treatment. PATIENTS AND METHODS: At each visit, toxicity was reported but severity was not graded routinely. Toxicity rates and performance status (PS) changes at three years were compared by chi(2) tests and logistic regression models in all the 3,866 of 4,004 patients eligible to the trial who received the allocated treatment. RESULTS: Only lung (fibrosis; dyspnoea; pneumonitis; any lung toxicities) (4.3% vs. 1.3%; p < 0.0001) but not cardiac toxicity (0.3% vs. 0.4%; p = 0.55) significantly increased with IM-MS treatment. No significant worsening of the PS was observed (p = 0.79), suggesting that treatment-related toxicity does not impair patient's daily activities. CONCLUSIONS: IM-MS irradiation seems well tolerated and does not significantly impair WHO PS at three years. A follow-up period of at least 10 years is needed to determine whether cardiac toxicity is increased after radiotherapy.

Published
2010
Full Text
View/download PDF

32. Outcome and prognostic factors in olfactory neuroblastoma: a rare cancer network study.

Author

Ozsahin, M., Gruber, G., Olszyk, O., Karakoyun-Celik, O., Pehlivan, B., Azria, D., Roelandts, M., Kaanders, J.H.A.M., Cengiz, M., Krengli, M., Matzinger, O., Zouhair, A., Ozsahin, M., Gruber, G., Olszyk, O., Karakoyun-Celik, O., Pehlivan, B., Azria, D., Roelandts, M., Kaanders, J.H.A.M., Cengiz, M., Krengli, M., Matzinger, O., and Zouhair, A.

Abstract

Contains fulltext : 89898.pdf (publisher's version ) (Closed access), PURPOSE: To assess the outcome in patients with olfactory neuroblastoma (ONB). METHODS AND MATERIALS: Seventy-seven patients treated for nonmetastatic ONB between 1971 and 2004 were included. According to Kadish classification, there were 11 patients with Stage A, 29 with Stage B, and 37 with Stage C. T-classification included 9 patients with T1, 26 with T2, 16 with T3, 15 with T4a, and 11 with T4b tumors. Sixty-eight patients presented with N0 (88%) disease. RESULTS: Most of the patients (n = 56, 73%) benefited from surgery (S), and total excision was possible in 44 patients (R0 in 32, R1 in 13, R2 in 11). All but five patients benefited from RT, and chemotherapy was given in 21 (27%). Median follow-up period was 72 months (range, 6-315). The 5-year overall survival (OS), disease-free survival (DFS), locoregional control, and local control were 64%, 57%, 62%, and 70%, respectively. In univariate analyses, favorable factors were Kadish A or B disease, T1-T3 tumors, no nodal involvement, curative surgery, R0/R1 resection, and RT-dose 54 Gy or higher. Multivariate analysis revealed that the best independent factors predicting the outcome were T1-T3, N0, R0/R1 resection, and total RT dose (54 Gy or higher). CONCLUSION: In this multicenter retrospective study, patients with ONB treated with R0 or R1 surgical resection followed by at least 54-Gy postoperative RT had the best outcome. Novel strategies including concomitant chemotherapy and/or higher dose RT should be prospectively investigated in this rare disease for which local failure remains a problem.

Published
2010

49. 6032 Helical tomotherapy (HT) for the treatment of anal canal cancer: preliminary clinical results, and dosimetric comparison between HT and intensity-modulated or 3D conformal radiotherapy

Author

Ugurluer, G., primary, Ballerini, G., additional, Letenneur, G., additional, Lacombe, C., additional, Pissaturo, O., additional, Matzinger, O., additional, Montemurro, M., additional, Zouhair, A., additional, Mirimanoff, R.O., additional, and Ozsahin, M., additional

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results